Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | GLS | O94925 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28063864 | 0.98 | KDM4E (0.53) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL28573962 | 0.94 | KDM4E (0.50) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL23212559 | 0.94 | HPGD (0.55) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL9238271 | 0.94 | KDM4E (0.50) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL28304217 | 0.91 | GPR119 (0.56) | KDM4EPKMHPGDGPR119RECQL | |
| SCHEMBL345306 | 0.90 | KDM4E (0.49) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL345307 | 0.90 | KDM4E (0.49) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL874037 | 0.90 | KDM4E (0.49) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL30002624 | 0.89 | KDM4E (0.46) | KDM4EPKMHPGDGPR119GLS | |
| SCHEMBL28589778 | 0.87 | KDM4E (0.47) | KDM4EPKMHPGDGPR119GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-109053551-A | The high-efficiency synthesis method of 4- piperidineacetate | 苏州盖德精细材料有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-104744549-B | Betulic acid derivant and preparation method thereof and the application in antitumor drug is prepared | 华东师范大学 | 2017-03-29 | — | — | CN | claimed |
| CN-103772477-B | Glycyrrhetinic acid derivative shown in formula (I), preparation method thereof and application | UNIV EAST CHINA NORMAL | 2015-07-08 | — | — | CN | claimed |
| CN-104744549-A | Betulinic acid derivative as well as preparation method and application thereof in preparing antineoplastic drugs | UNIV EAST CHINA NORMAL | 2015-07-01 | — | — | CN | claimed |
| CN-103772477-A | Glycyrrhetinic acid derivative shown in formula (I), preparation method thereof and application | UNIV EAST CHINA NORMAL | 2014-05-07 | — | — | CN | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0638553-A1 | Carboxylic acid amides having a terminal carboxylic acid group as aggregation inhibiting drugs | Dr. Karl Thomae GmbH (DE) | 1995-02-15 | — | — | EP | disclosed |
| WO-1995000472-A1 | 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS | ZENECA LIMITED (GB) | 1995-01-05 | — | — | WO | disclosed |
| EP-0632016-A1 | 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors | ZENECA LIMITED (GB) | 1995-01-04 | — | — | EP | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | CDK9, CDK20, CDK19 | KDM4E 1181/4885PKM 3062/4885HPGD 2905/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | KDM4E 3983/4885PKM 4010/4885HPGD 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.